Due to popular demand and customer requests, we have opened up the distribution network of authorised pharmacy stockists to enable more customers to access Nuceiva® (botulinum toxin type A) through their preferred supplier. The Evolus UK distributor partnership network includes HealthXChange and Medfx in addition to Wigmore, who helped with the launch of Nuceiva® into the market in Great Britain. These pharmacy distributors are well established and provide the medical aesthetics community with leading products. “We understand the importance of choice, and that’s why we are pleased to be expanding access to Nucevia®, our botulinum toxin,’ said Suse Alexander, General Manager, Evolus UK. “Giving customers choice as we evolve the aesthetics market is in our DNA. Partnering with additional pharmacy suppliers will make it easier for customers to order through their preferred provider.” To find out more, go directly to your pharmacy of choice or connect with the Evolus UK Multi-Channel Managers

Glabellar lines are not just about the classic ‘11s’ shape. At the BACN Fall congress, Dr David Eccleston explored the anatomy of the key glabellar patterns and what this can mean for clinical practice. in his podium presentation with Evolus, he reviewed the science behind Nuceiva®▼(botulinum toxin type A) and shared why his patients are loving it so much. The British Association of Cosmetic Nurses is the largest Professional Association for nurses carrying out medical aesthetic treatments in the UK.  If you missed this event but want to learn about what's coming next, share your interest ins events with Evolus below

Improving patient outcomes is an important conversation for the medical aesthetics community. That's why Evolus was pleased to attend the CMAC congress in London. Our Medical Affairs team was on hand to shared their views with CMAC attendee's. Complications in Medical Aesthetic Collaborative (CMAC) is a Not-for-Profit organisation established in 2020 to support clinicians worldwide in diagnosing and managing complications in medical aesthetics. At Evolus we are also big fans of appropriate reporting adverse events and actively encourage HCPs to do this through the usual channels. You can find the details easily at the bottom of this page. By the way, did you spot the black triangle! Here’s what it means: This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events. Reporting forms and information can be found at yellowcard.mhra.gov.au

Early one Saturday morning in September, the Evolus team installed 3 heads at Church House in Westminster. This isn’t the start of a sinister movie but rather about education. The 3D heads displayed facial muscle anatomy and formed part of the Evolus pop up booth at the BCAM autumn congress. Combining information exchange with details about Nuceiva®(botulinum toxin type A) the team played host to plenty of BCAM members. A big shout out for their curiosity and engagement to evolve the future of beauty. The British College of Aesthetic Medicine (BCAM) is the UK's leading representative body for doctors and dentists practising aesthetic medicine. This promotional event was funded by Evolus and intended for UK healthcare professionals only.